Last reviewed · How we verify
Moderately severe pneumonia — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Bicillin C-R | Penicillin G Benzathine | Pfizer Inc. | Beta-lactam antibiotic | Cell-wall peptidoglycan biosynthesis |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Moderately severe pneumonia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Moderately severe pneumonia:
- Moderately severe pneumonia treatment updates — RSS
- Moderately severe pneumonia treatment updates — Atom
- Moderately severe pneumonia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Moderately severe pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moderately-severe-pneumonia. Accessed 2026-06-10.
Related
- Moderately severe pneumonia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing